|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Clinical Therapy Trials-Drug |
Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021
3 Address correspondence and reprint requests to Lauren E. Abrey, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.
Temozolomide is an effective agent in the treatment of recurrent malignant gliomas. The standard dosage is 150-200 mg/m2 per day for 5 days in a 28-day cycle. A prior phase I study established a chronic daily temozolomide dose that significantly increased the total dose administered and suggested a superior response rate. In a prospective phase II trial, we treated 35 patients with recurrent malignant gliomas with temozolomide 75 mg/m2 per day for 42 consecutive days in a 70-day cycle. Median age was 55 years (range, 27-73 years) and median Karnofsky performance score was 70 (range, 60-90). Twenty-eight (79%) patients had glioblastoma multiforme, 3 (9%) anaplastic astrocytoma, 2 (6%) anaplastic oligodendroglioma, and 2 (6%) anaplastic oligoastrocytoma. All but one had prior radiotherapy, and 27 had prior chemotherapy. There were 2 partial (anaplastic astrocytoma) and 3 minor (glioblastoma multiforme) radiographic responses; 17 patients had progressive disease at the end of the first cycle. In 55 cycles of temozolomide, there were 8 episodes of asymptomatic drug-related grade 3 toxicity: 6 lymphopenia, 1 neutropenia, and 1 thrombocytopenia. Median progression-free survival and overall survival were 2.5 and 8.7 months (2.3 and 7.7 months in glioblastoma multiforme patients). At 6 months, progression-free survival and overall survival rates were 27% and 67% (19% and 60% in glioblastoma multiforme). Quality of life scores did not change significantly during treatment. We conclude that the extended low-dose schedule of temozolomide is well tolerated in heavily pretreated patients; however, our results do not support an improved rate of response or survival.
Bower, M., Newlands, E.S., Bleehen, N.M., Brada, M., Begent, R.J., Calvert, H., Colquhoun, I., Lewis, P., and Brampton, M.H. (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother. Pharmacol. 40, 484-488.[CrossRef][ISI][Medline]
Brock, C.S., Newlands, E.S., Wedge, S.R., Bower, M., Evans, H., Colquhoun, I., Roddie, M., Glaser, M., Brampton, M.H., and Rustin, G.J. (1998) Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res. 58, 4363-4367.
Cella, D.F., Tulsky, D.S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., Silberman, M., Yellen, S.B., Winicour, P., Brannon, J., Eckberg, K., Lloyd, S., Purl, S., Blendowski, C., Goodman, M., Barnicle, M., Stewart, I., McHale, M., Bonomi, P., Kaplan, E., Taylor IV, S., Thomas, C.R., and Harris, J. (1993) The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J. Clin. Oncol. 11, 570-579.
Fine, H.A., Dear, K.B., Loeffler, J.S., Black, P.M., and Canellos, G.P. (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71, 2585-2597.[CrossRef][ISI][Medline]
Fleming, T.R. (1982) One sample multiple testing procedure for phase II clinical trials. Biometrics 38, 143-151.[CrossRef][ISI][Medline]
Kaplan, E.L., and Meier, P. (1958) Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457-481.[CrossRef][ISI]
Macdonald, D.R., Cascino, T.L., Schold, S.C., and Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. J. Clin. Oncol. 8, 1277-1280.[Abstract]
Medical Research Council Brain Tumor Working Party (2001) Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A Medical Research Council trial. J. Clin. Oncol. 19, 509-518.
Newlands, E.S., Blackledge, G.R., Slack, J.A., Rustin, G.J., Smith, D.B., Stuart, N.S., Quarterman, C.P., Hoffman, R., Stevens, M.F., Brampton, M.H., and Gibson, A.C. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br. J. Cancer 65, 287-291.[ISI][Medline]
Osoba, D., Brada, M., Yung, W.K., and Prados, M.D. (2000a) Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur. J. Cancer 36, 1788-1795.[CrossRef][ISI][Medline]
Osoba, D., Brada, M., Yung, W.K., and Prados, M. (2000b) Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol. 18, 1481-1491.
Stevens, M.F., Hickman, J.A., Langdon, S.P., Chubb, D., Vickers, L., Stone, R., Baig, G., Goddard, C., Gibson, N.W., and Slack, J.A. (1987) Antitumor activity and pharmacokinetics in mice of 8–carbamoyl-3–methyl-imidazo[5,1–d]-1,2,3,5–tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res. 47, 5846-5852.
Stupp, R., Ostermann, S., Dietrich, P.-Y., Pica, A., Maillard, I., Maeder, P.H., Miralbell, R., Collao, C., Decosterd, L., Villemure, J.G., de Tribolet, N., Leyvraz, S., and Mirimanoff, R.O. (2000) Daily temozolomide (TMZ) and concomitant radiation followed by adjuvant TMZ for newly diagnosed glioblastoma multiforme (GBM). Neuro-Oncol. [serial online], Doc 00–D208, September 21, 2000. URL http://neuro-oncology.mc.duke.edu. Neuro-Ocol. 2, 296. (abstract)
Weitzner, M.A., Meyers, C.A., Gelke, C.K., Byrne, K.S., Cella, D.F., and Levin, V.A. (1995) The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 75, 1151-1161.[CrossRef][ISI][Medline]
Wong, E.T., Hess, K.R., Gleason, M.J., Jaeckle, K.A., Kyritsis, A.P., Prados, M.D., Levin, V.A., and Yung, W.K.A. (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J. Clin. Oncol. 17, 2572-2578.
Yung, W.K., Prados, M.D., Yaya-Tur, R., Rosenfeld, S.S., Brada, M., Friedman, H.S., Albright, R., Olson, J., Chang, S.M., O'Neill, A.M., Friedman, A.H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V.A. (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol. 17, 2762-2771.
Yung, W.K., Albright, R.E., Olson, J., Fredericks, R., Fink, K., Prados, M.D., Brada, M., Spence, A., Hohl, R.J., Shapiro, W., Glantz, M., Greenberg, H., Selker, R.G., Vick, N.A., Rampling, R., Friedman, H., Phillips, P., Bruner, J., Yue, N., Osoba, D., Zaknoen, S., and Levin, V.A. (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br. J. Cancer 83, 588-593.[CrossRef][ISI][Medline]
This article has been cited by other articles:
|
|
 |
|
  E. T. Wong, A. A. Brandes, and A. Tosoni Is protracted low-dose temozolomide feasible in glioma patients? Neurology, August 8, 2006; 67(3): 543 - 544. [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Fruehauf, H. Brem, S. Brem, A. Sloan, G. Barger, W. Huang, and R. Parker In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas Clin. Cancer Res., August 1, 2006; 12(15): 4523 - 4532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Y. Eyupoglu, E. Hahnen, C. Trankle, N. E. Savaskan, F. A. Siebzehnrubl, R. Buslei, D. Lemke, W. Wick, R. Fahlbusch, and I. Blumcke Experimental therapy of malignant gliomas using the inhibitor of histone deacetylase MS-275 Mol. Cancer Ther., May 1, 2006; 5(5): 1248 - 1255. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tosoni, G. Cavallo, M. Ermani, L. Scopece, E. Franceschi, C. Ghimenton, M. Gardiman, L. Pasetto, V. Blatt, and A. A. Brandes Is protracted low-dose temozolomide feasible in glioma patients? Neurology, February 14, 2006; 66(3): 427 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Quinn, A. Desjardins, J. Weingart, H. Brem, M. E. Dolan, S. M. Delaney, J. Vredenburgh, J. Rich, A. H. Friedman, D. A. Reardon, et al. Phase I Trial of Temozolomide Plus O6-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma J. Clin. Oncol., October 1, 2005; 23(28): 7178 - 7187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Chamberlain, D. D. Tsao-Wei, and S. Groshen Temozolomide for treatment-resistant recurrent meningioma Neurology, April 13, 2004; 62(7): 1210 - 1212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.B. Su, S. Sohn, S. E. Krown, P. O. Livingston, J. D. Wolchok, C. Quinn, L. Williams, T. Foster, K. A. Sepkowitz, and P. B. Chapman Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications J. Clin. Oncol., February 15, 2004; 22(4): 610 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Chua, M. A. Rosenthal, S. S. Wong, D. M. Ashley, A.-m. Woods, A. Dowling, and L. M. Cher Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme Neuro-oncol, January 1, 2004; 6(1): 38 - 43. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Pace, A. Vidiri, E. Galie, M. Carosi, S. Telera, A. M. Cianciulli, P. Canalini, D. Giannarelli, B. Jandolo, and C. M. Carapella Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response Ann. Onc., December 1, 2003; 14(12): 1722 - 1726. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
